Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunlei Ke

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Biostatistics (Oxford, England)|May 21, 2019
Bayesian adaptive basket trial design using model averagingMatthew A Psioda, Jiawei Xu, Qi Jiang, et al.
Journal of Biopharmaceutical Statistics|February 28, 2015
A counterfactual p-value approach for benefit-risk assessment in clinical trialsDonglin Zeng, Ming-Hui Chen, Joseph G Ibrahim, et al.
Kidney International Reports|November 29, 2023
Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular DiseasesBradley P Dixon, Larry A Greenbaum, Liwei Huang, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 8, 2011
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
The Journal of Urology|October 20, 2009
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Sarcopenia during androgen-deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
The New England Journal of Medicine|August 13, 2009
Denosumab in men receiving androgen-deprivation therapy for prostate cancerMatthew R Smith, Blair Egerdie, Narciso Hernández Toriz, et al.
BMJ Neurology Open|June 20, 2022
Chronic lesion activity and disability progression in secondary progressive multiple sclerosisVanessa Beynon, Ilena C George, Colm Elliott, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Biostatistics (Oxford, England)|May 21, 2019
Bayesian adaptive basket trial design using model averagingMatthew A Psioda, Jiawei Xu, Qi Jiang, et al.
Journal of Biopharmaceutical Statistics|February 28, 2015
A counterfactual p-value approach for benefit-risk assessment in clinical trialsDonglin Zeng, Ming-Hui Chen, Joseph G Ibrahim, et al.
Kidney International Reports|November 29, 2023
Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular DiseasesBradley P Dixon, Larry A Greenbaum, Liwei Huang, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 8, 2011
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
The Journal of Urology|October 20, 2009
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Sarcopenia during androgen-deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
The New England Journal of Medicine|August 13, 2009
Denosumab in men receiving androgen-deprivation therapy for prostate cancerMatthew R Smith, Blair Egerdie, Narciso Hernández Toriz, et al.
BMJ Neurology Open|June 20, 2022
Chronic lesion activity and disability progression in secondary progressive multiple sclerosisVanessa Beynon, Ilena C George, Colm Elliott, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
Pageof 2